US Influenza Vaccine Antigen and Adjuvant Orders for 2009 (H1N1)

By admin | Jun 13, 2009
Manufacturer Bulk Vaccine Antigen Oil-In-Water Bulk Adjuvant
Novartis $150 million $139 million
GlaxoSmithKline $ 38 million $144 million
Sanofi $191 million
CSL Biotherapies $180 million
MedImmune $ 90 million
Total $649 million $283 million

HHS has contracted with these manufacturers that currently hold U.S. licenses for flu vaccine as part of the National Strategy for Pandemic Influenza. In May 2009, HHS issued new orders on these contracts to produce a bulk supply of vaccine antigen and adjuvant and to produce pilot (also called investigational) lots of a 2009 H1N1 vaccine. Most will be stored in bulk, and a small amount will be prepared as vaccine for use in clinical studies to evaluate vaccine safety and the dosage required for a protective effect. This research will include studies with adjuvant to determine its safety and the effect it would have on the immune system’s response.

Leave a Comment

If you would like to make a comment, please fill out the form below.

Name (required)

Email (required)

Website

Comments

© 2007 Vaccine Market, - WordPress Themes by DBT